NEW YORK (GenomeWeb) – Biocept said today that it has reached an agreement for the validation and potential adoption of its Target Selector liquid biopsy kits in Agiomix's lab in the United Arab Emirates lab.
Agiomix will test the kits to ensure comparability of results achieved in Biocept's San Diego CLIA-certified, CAP-accredited facility. Subject to that validation, Agiomix would then purchase the kits for use in its genomics test services, analyzing samples received from the Middle East, Africa, and Asia.
Biocept CEO Michael Nall said in a statement that the agreement would make Agiomix its first customer for the newly launched liquid biopsy kits.
"Our strategy is to enable molecular laboratories around the world to exclusively license and utilize our technologies, including test kits and blood collection tubes … as we seek to create a leading global brand," he added.
Agiomix CEO John Clarkson said his firm's focus "is to provide tumor biomarker testing services to support the initiatives of global biotherapeutics companies that are bringing leading-edge targeted cancer therapies to emerging markets, and therefore we are dedicated to bringing the best-in-class liquid biopsy technologies into our laboratory." Â
Financial and other terms of the deal were not disclosed.